Prostate Cancer

“The impact of precision medicine in prostate cancer has been significant over a relatively brief period,” says Leonard G. Gomella, MD, FACS.

"[Now that] we have entered the era of precision and personalized medicine, well-designed clinical trials are needed to address selected focused questions regarding optimal therapy sequencing,” says Maha H.A. Hussain, MBChB.

Drs Helfand, Chapin, and Collins, review the case of 67-year-old man treated with recurring prostate cancer.

Clinical oncologists present the case of a 62-year-old man with recurrent prostate cancer.

“Our conclusion was that the amount of pattern 3 in men with grade groups 2, 3, and 4 is not predictive of oncologic outcome once you know the amount of 4,” says Andrew J. Vickers, PhD.

"We are confident in PT-112's potential as an effective treatment for patients with mCRPC who have progressed on androgen receptor directed therapy, chemotherapy or radioligand therapy and who lack any effective immunotherapy," says Robert Fallon.

Overall, lesions less than 5 mm in size were detected across readers in 14% (7 of 50) of patients.

"We're going to look at whether that difference in the protocol has clinically meaningful implications, such as are patients who receive antibiotic prophylaxis at higher risk of developing resistance in the future?" says Badar M. Mian, MD.

"I think that the heat map is a very intuitive tool. It comes in a 3-dimensional structure so you can move it around," says Wayne G. Brisbane, MD.

"We found that PSA levels vary by ethnicity, Black men had higher PSA levels than White men, and Asian men had the lowest PSA levels,” says Elizabeth Down.

"The biggest finding was that the guys lost the weight. They lost 5.5% of their body weight," says Jill M. Hamilton Reeves, PhD, RD, CSO.

“This significant milestone not only celebrates ArteraAI's success but also paves the way for the integration of AI-enabled solutions into clinical practice, illustrating their potential to enhance personalized patient care," says Andre Esteva.

Experts in prostate cancer evaluate the data from the SPOTLIGHT trial and the use of 18F-rhPSMA-7.3 for prostate cancer.

A panel of experts introduce the SPOTLIGHT study, evaluating PSMA PET in patients with prostate cancer.

“The test is designed to non-invasively identify the presence of aggressive cancer in men already diagnosed with prostate cancer who are on or are considering starting active surveillance,” says Kirk J. Wojno, MD.

"We looked at people who were in the intermediate-risk zone, and we found that our calculator did do a better job of helping some of those men avoid unnecessary biopsies," says Adam B. Murphy, MD, MBA, MSCI.

“What we found was that the rate of complications due to infection were 2.6% with the transrectal approach, and 2.7% with the transperineal,” says Badar M. Mian, MD.

The guideline includes 30 recommendations related to salvage therapy for patients with biochemical recurrence following primary curative treatment for prostate cancer.

The Decipher test is a 22-gene prognostic tool used for the risk stratification of patients with localized prostate cancer.

“These clinical data show encouraging safety and efficacy with JANX007 in metastatic castration-resistant prostate cancer and with JANX008 in late-stage solid tumors," says David Campbell, PhD.

“In this study, we sought to compare our early outcomes with transperineal prostate biopsy compared to transrectal,” says Saum B. Ghodoussipour, MD.

"We had interest in trying to look at mechanisms and seeing if the obvious question is, well, if obesity is associated with progressing cancer, can we disrupt that link if we help men lose weight in a healthy way," says Jill Hamilton Reeves, PhD, RD, CSO.

Clara Hwang, MD, is the lead author of the study, “Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.”

“It seems that DRE does not add a clinically or statistically significant [benefit] to PSA testing alone in detecting prostate cancer,” says Shahrokh F. Shariat, MD.

Dr. Chapin and fellow expert oncologists discuss the latest data from the LIGHTHOUSE trial, evaluating 18F-rhPSMA-7.3 for staging patients with prostate cancer.

Oncologists share their clinical perspectives of PSMA PET imaging and the results of the patient case.

“Our hope is to really change the practice of medicine,” says Jim C. Hu, MD, MPH.

The CELC-G-201 trial is assessing the safety, preliminary efficacy, and pharmacokinetics of gedatolisib plus darolutamide in mCRPC

"Overall, our conclusion is we observed more benefit in apalutamide vs abiraterone," says Mehmet Asim Bilen, MD.

“The patients with CDK12, the combination had a PSA50 of about 83% compared to the ABI/placebo of about only 62%,” says Neal D. Shore, MD.